Welcome to our dedicated page for bioAffinity Tech news (Ticker: BIAFW), a resource for investors and traders seeking the latest updates and insights on bioAffinity Tech stock.
News about bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) centers on its work in noninvasive lung cancer diagnostics and related lung disease research. The company’s disclosures describe CyPath® Lung, a sputum-based test that uses advanced flow cytometry and artificial intelligence (AI) to detect cell populations indicative of malignancy. Clinical data reported by bioAffinity show high sensitivity, specificity and accuracy for detecting lung cancer in high-risk patients with small lung nodules, including cases identified at Stage 1A.
Readers following BIAFW news will see updates on clinical and real-world case studies where CyPath® Lung contributed to early diagnosis or helped avoid unnecessary invasive procedures. Company announcements also highlight presentations at professional meetings, such as pulmonary and cancer-focused conferences, where research on CyPath® Lung’s processing methods, sample handling and diagnostic performance is shared with clinicians and researchers.
Another key news theme is laboratory quality and accreditation. bioAffinity reports that its subsidiary Precision Pathology Laboratory Services (PPLS) maintains College of American Pathologists (CAP) accreditation and CLIA certification, which the company associates with quality, accuracy and patient safety across its diagnostic services, including CyPath® Lung.
Investors and healthcare professionals can also expect news on intellectual property developments, such as U.S. and international patents covering the AI-built diagnostic algorithm and the broader flow cytometry platform for assessing lung health and multiple lung diseases. In addition, corporate and financial news items describe equity financings, warrant-related transactions, and commentary from management linking revenue trends and operating decisions to the commercialization of CyPath® Lung.
For those tracking BIAFW, the news flow provides context on how bioAffinity is advancing its noninvasive diagnostic platform, expanding clinical use of CyPath® Lung, and managing its capital structure and Nasdaq listing status.
BioAffinity Technologies (Nasdaq: BIAF; BIAFW) has reported a significant 139% growth in the number of pulmonology practices offering its noninvasive CyPath® Lung test for early-stage lung cancer detection since January 1, 2024. Sales outpaced Q1 2024 targets, leading to expansion beyond Texas to eight additional states. The company increased its 2023 sales forecast by 35% in May. This growth is attributed to positive physician-to-physician word of mouth and effective marketing strategies. CyPath® Lung's high sensitivity, specificity, and accuracy have been well-received by the medical community. The lung cancer diagnostics market is projected to reach $4.7 billion by 2030.
BioAffinity Technologies (Nasdaq: BIAF; BIAFW) reports record Q1 2024 revenue of $2.4 million, driven by CyPath® Lung sales and increased lab volumes. CyPath® Lung orders surged by 547% annualized in the first four months of 2024 over 2023, leading to a 35% increase in the 2024 sales forecast. The number of physician offices ordering the test doubled since January 2024, expanding beyond Texas to states like Pennsylvania and New Jersey. Medicare reimbursement for CyPath® Lung began on January 1, 2024. Precision Pathology Laboratory Services forecasts $9.2-$9.6 million in 2024 revenues, up 23% from 2023. The company reported an increase in R&D and SG&A expenses, resulting in a net loss of $2.1 million for Q1 2024, compared to a net loss of $1.5 million in Q1 2023. BioAffinity closed a $2.5 million funding round to support growth and continued product development in collaboration with the DoD.
bioAffinity Technologies, Inc. (Nasdaq: BIAF) reports an increase in sales of CyPath® Lung, their noninvasive diagnostic test for lung cancer detection. April sales were up 21% from March, with new orders from physicians in various states. The company also welcomed new team members to support the CyPath® Lung product launch. Additionally, bioAffinity will present research at the American Thoracic Society's Annual Conference.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.